# US 2025/0367171 A1 · Therapeutic or prophylactic agent for peripheral neuropathies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367171 A1
- Document ID: US20250367171A1
- Status: Published application
- Kind: A1
- Application number: 19/305,965
- Filed: 2025-08-21
- Published: 2025-12-04
- Earliest claimed: 2017-03-31
- Assignees: Toray Industries, Inc.
- Applicants: Toray Industries, Inc.
- Inventors: Kojiro Hara; Tomohiko Suzuki; Chihiro Yoshida; Koji Takeo; Koji Shimoda; Naoki Izumimoto; Kazumi Nishimura; Rieko Naguro
- Web page: https://patentgrep.com/patent/US20250367171A1

## CPC

- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61P 25/02: for peripheral neuropathies
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A method of treating or preventing peripheral neuropathies includes administering a therapeutically effective amount of a cyclic amine derivative represented by general formula (I) or a pharmacologically acceptable salt thereof to a patient who needs treatment wherein, carbon marked with * is asymmetric carbon; and A represents a group represented by general formulae (IIa), (IIb) or (IIc): wherein R1 represents a methyl group or an ethyl group optionally substituted with a halogen atom, R2 represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms, each R3 independently represents a methyl group or an ethyl group, and n represents 1 or 2.

## Claims

### Claim 1

A method of treating a symptom of a peripheral neuropathy, the method comprising:
selecting a patient diagnosed with peripheral neuropathy having one or more symptom of motor neuropathy selected from muscle weakness, muscle atrophy, flaccid paralysis, deep tendon reflex decrease, deep tendon reflex loss, and/or one or more symptom of an autonomic neuropathy selected from constipation, abdominal pain, dyshidrosis, dysuria, orthostatic hypotension, wherein said patient is in need of treatment thereof,
administering a therapeutically effective amount of a cyclic amine derivative represented by general formula (I) or a pharmacologically acceptable salt thereof to the selected patient
wherein,
carbon marked with * is asymmetric carbon; and
A represents a group represented by general formulae (IIa), (IIb) or (IIc):
wherein R1 represents a methyl group or an ethyl group optionally substituted with one or more halogen atoms,
R2 represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms,
each R3 independently represents a methyl group or an ethyl group, and
n represents 1 or 2.

### Claim 2 (depends on 1)

The method according to claim 1, wherein A is the group represented by general formula (IIa).

### Claim 3 (depends on 1)

The method according to claim 1, wherein A is the group represented by general formulae (IIb) or (IIc).

### Claim 4 (depends on 1)

The method according to claim 1, wherein A is the group represented by general formula (IIa) and a stereochemical configuration of the asymmetric carbon marked with * is S.

### Claim 5 (depends on 1)

The method according to claim 1, wherein R1 represents a methyl group or an ethyl group optionally substituted with one or more fluorine atoms.

### Claim 6 (depends on 1)

The method according to claim 1, wherein R1 is a methyl group, an ethyl group, a difluoromethyl group or a 2,2,2-trifluoroethyl group.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the peripheral neuropathies are drug-induced peripheral neuropathies.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the drug-induced peripheral neuropathies are at least one selected from the group consisting of anticancer agent-induced peripheral neuropathy, antiviral agent-induced peripheral neuropathy, antimicrobial agent-induced peripheral neuropathy, antitubercular agent-induced peripheral neuropathy, antiarrhythmic agent-induced peripheral neuropathy, lipid-lowering drug-induced peripheral neuropathy, immunosuppressive drug-induced peripheral neuropathy, gout therapeutic agent-induced peripheral neuropathy and peripheral neuropathies induced by other drugs.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the peripheral neuropathies are autoimmune peripheral neuropathies.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the autoimmune peripheral neuropathies are at least one selected from the group consisting of Guillain-Barre syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy and paraproteinemic neuropathy.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the peripheral neuropathies are metabolic peripheral neuropathies.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the metabolic peripheral neuropathies are at least one selected from the group consisting of diabetic peripheral neuropathy, uremic peripheral neuropathy, collagen-peripheral neuropathy and vitamin deficiency peripheral neuropathy.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the peripheral neuropathies are hereditary peripheral neuropathies.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the hereditary peripheral neuropathies are at least one selected from the group consisting of Charcot-Marie-Tooth disease, familial amyloid polyneuropathy, hereditary neuropathy to pressure palsies (HNPP) and hereditary neuralgic amyotrophy.

### Claim 15

A method of suppressing the development of drug-induced peripheral neuropathies caused by a drug, comprising administering a therapeutically effective amount of a cyclic amine derivative represented by general formula (I) or a pharmacologically acceptable salt thereof to a patient to whom the drug is administered and who needs prevention or reduction of the development of the peripheral neuropathies:
wherein,
carbon marked with * is asymmetric carbon; and
A represents a group represented by general formulae (IIa), (IIb) or (IIc):
wherein R1 represents a methyl group or an ethyl group optionally substituted with one or more halogen atoms,
R2 represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms,
each R3 independently represents a methyl group or an ethyl group, and
n represents 1 or 2.

### Claim 16 (depends on 15)

The method according to claim 15, wherein A is the group represented by general formula (IIa).

### Claim 17 (depends on 15)

The method according to claim 15, wherein A is the group represented by general formulae (IIb) or (IIc).

### Claim 18 (depends on 15)

The method according to claim 15, wherein A is the group represented by general formula (IIa) and a stereochemical configuration of the asymmetric carbon marked with * is S.

### Claim 19 (depends on 15)

The method according to claim 15, wherein R1 represents a methyl group or an ethyl group optionally substituted with one or more fluorine atoms.

### Claim 20 (depends on 15)

The method according to claim 15, wherein R1 is a methyl group, an ethyl group, a difluoromethyl group or a 2,2,2-trifluoroethyl group.

### Claim 21 (depends on 15)

The method according to claim 15, wherein the drug-induced peripheral neuropathies are at least one selected from the group consisting of anticancer agent-induced peripheral neuropathy, antiviral agent-induced peripheral neuropathy, antimicrobial agent-induced peripheral neuropathy, antitubercular agent-induced peripheral neuropathy, antiarrhythmic agent-induced peripheral neuropathy, lipid-lowering drug-induced peripheral neuropathy, immunosuppressive drug-induced peripheral neuropathy, gout therapeutic agent-induced peripheral neuropathy and peripheral neuropathies induced by other drugs.

### Claim 22

A method of treating peripheral neuropathy characterized by autonomic dysfunction, the method comprising:
selecting a patient diagnosed with peripheral neuropathy exhibiting at least one symptom selected from the group consisting of orthostatic hypotension, constipation, dysuria, or dyshidrosis, and
administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof,
wherein,
carbon marked with * is asymmetric carbon; and
A represents a group represented by general formulae (IIa), (IIb) or (IIc):
wherein R1 represents a methyl group or an ethyl group optionally substituted with one or more halogen atoms,
R2 represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms,
each R3 independently represents a methyl group or an ethyl group, and
n represents 1 or 2;
wherein the patient does not exhibit neuropathic pain.
